Search
Trefentanil
go.drugbank.com/drugs/DB09181ExperimentalTrefentanil (A-3665) is a fentanyl analogue opioid developed in 1992. It is more potent and shorter acting than alfentanil. … Trefentanil is not used in clinics due to the severity of its respiratory depression, though it is still used in research.
Benzoylecgonine
go.drugbank.com/drugs/DB01515ExperimentalIllicitBenzoylecgonine is the major metabolite of cocaine. It is formed by hydrolysis of cocaine in the liver, catalysed by carboxylesterases. … It is excreted in the urine of cocaine users after processing in the liver.
Synonyms: (1R,2R,3S,5S)-8-methyl-3-[(phenylcarbonyl)oxy]-8-azabicyclo[3.2.1]octane-2-carboxylic acidalpha-methylthiofentanyl
go.drugbank.com/drugs/DB01470ExperimentalIllicitalpha-methylthiofentanyl is an opioid analgesic that is an analog of fentanyl.
Lasalocid
go.drugbank.com/drugs/DB11423ExperimentalVet approvedLasalocid is an agent that presents antibacterial and coccidiostat activities. It is produced by strains of _Streptomyces lasaliensis_.
MORAb-066
go.drugbank.com/drugs/DB17347InvestigationalMORAb-066 is a humanized antibody directed against tissue factor (TF). It is being investigated in pancreatic cancer.
Oxaprotiline
go.drugbank.com/drugs/DB09307ExperimentalDextroprotiline is the S or dextro isomer of oxaprotiline (CGP-12,104-A). … Oxaprotiline is a norepinephrine reuptake inhibitor of the tetracyclic antidepressant family that is related to maprotiline. This drug was never marketed.
Befunolol
go.drugbank.com/drugs/DB09013ExperimentalBefunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.
Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen
go.drugbank.com/drugs/DB10801ApprovedInvestigationalNeisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria
Zorecimeran
go.drugbank.com/drugs/DB15843InvestigationalThe CVnCov Vaccine (or CV07050101) is in development by CureVac AG. … As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence Phase 1 clinical trials of this vaccine (NCT04449276).
Categories: Complex MixturesZYCOV-D
go.drugbank.com/drugs/DB15892ExperimentalAs of August, 2020 the candidate is in Phase II clinical trials[A219758]. … Once the plasmid DNA is introduced into host cells and the viral protein is translated, it elicits a strong immune response, stimulating the humoral and cellular components of the immune system[L16503]